Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Women First Healthcare IncfiledCriticalWomen First Healthcare Inc
Priority claimed from PCT/US2002/025754external-prioritypatent/WO2003015729A1/en
Publication of BR0211911ApublicationCriticalpatent/BR0211911A/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
"COMPOSIçãO TóPICA E MéTODO DE APLICAçãO TóPICA DE INIBIDOR DE CARBOXILASE DE ORNITINA". Polietileno glicol éter de um álcool de alquila, tendo a fórmula geral CH~ 3~(CH~ 2~)xCH~ 2~(OCH~ 2~CH~ 2~)~ n~OH, em que X é de 8 a 20 (dos quais ceteareth-20, esteareth-20 e esteareth-100 são os preferidos), poloxamer 185, poloxamer 407, N,N-dimetil dodecilamina N-óxido e suas misturas são empregados para aumentar a administração folicular e/ou tempo de residência folicular de certos inibidores de decarboxilase de ornitina solúveis em água, dos quais o ácido 2-(di-fluormetil)-2,5-diaminopentanóico e seus sais, hidratos, enatiómeros óticos e mistura racêmica são os preferidos."TOPIC COMPOSITION AND TOPICAL APPLICATION METHOD OF ORNITINE CARBOXYLASE INHIBITOR". Polyethylene glycol ether of an alkyl alcohol having the general formula CH ~ 3 ~ (CH ~ 2 ~) xCH ~ 2 ~ (OCH ~ 2 ~ CH ~ 2 ~) ~ n ~ OH, where X is from 8 to 20 (of which ceteareth-20, esteareth-20 and esteareth-100 are preferred), poloxamer 185, poloxamer 407, N, N-dimethyl dodecylamine N-oxide and mixtures thereof are employed to increase follicular administration and / or residence time. certain water-soluble ornithine decarboxylase inhibitors, of which 2- (difluoromethyl) -2,5-diaminopentanoic acid and its salts, hydrates, optical enantiomers and racemic mixture are preferred.
BR0211911-0A2001-08-152002-08-13
Topical composition and method of topical application of ornithine carboxylase inhibitor
BR0211911A
(en)
Pharmaceutical composition, method for preparing same, methods for inhibiting the rate of precipitation of the solution agent in the GI tract, and for reducing inter-patient variability with respect to bioavailability and / or plasma concentrations of the agent, and use of a water soluble ether cellulose or an ester of a water soluble ether cellulose